Clinical dilemmas and a review of strategies to manage drug shortages

Journal of Pharmacy Practice

Volumn 26, Issue 3, 2013, Pages 183-191

  Rider, Anne Elise ^a   Templet, Derek J ^b   Daley, Mitchell J ^c   Shuman, Carrie ^c   Smith, Leticia V ^a,d  

^a Seton Medical Center Austin   (United States)

^b South Austin Medical Center   (United States)

^c University Medical Center Brackenridge   (United States)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

chemotherapy; drug shortages; propofol; sedation

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVERSE OUTCOME; ARTICLE; CANCER PATIENT; CRITICALLY ILL PATIENT; DRUG MANUFACTURE; DRUG SHORTAGE; HEALTH CARE PERSONNEL; HUMAN; PATIENT SAFETY; SEDATION; TREATMENT OUTCOME; VULNERABLE POPULATION;

EID: 84878917259     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190013482332     Document Type: Article

References (46)

1. Drug shortage: current drugs. (Updated April 4, 2012). The American Society of Health-System Pharmacists (ASHP) Web Site. http://www.ashp.org/ DrugShortages/Current/. Accessed April 5, 2012.
2. The Associated Press. 2011 medication shortages set new record at 267. http://finance.yahoo.com/news/2011-medication-shortages-set-apf-4010610976.html. Accessed November 24, 2012.
3. ArpinoPFoxER. Establish a Robust Drug Shortages Program. Pharmacy purchasing and products Web Site. http://www.pppmag.com/article/1044/January- 2012/Establish-a-Robust-Drug-Shortages-Program/. Accessed March 31,2011.
4. Kaakeh R, Sweet BV, Reilly C, et al. Impact of drug shortages on U.S. health-systems. Am J Health-Syst Pharm. 2011 ; 68 (19). 1811-1819
5. Fox ER, James KB, Kokko H, et al. ASHP guidelines on managing drug product shortages in hospitals and health systems. Am J Health-Syst Pharm. 2009 ; 66 (15). 1399-1406
6. Guidance for industry. Planning for the effects of high absenteeism to ensure availability of medically necessary drug products. (Updated March 2011). U.S. Food and Drug Administration Web Site. http://www.fda.gov/ucm/groups/ fdagov-public/@fdagov-drugs-gen/documents/document/ucm196497.pdf. Accessed March 18, 2012.
7. Medications Safety Alert. Drug shortages threaten patient safety (Updated September 23, 2010). Institute for Safe Medication Practices Web Site. http://www.ismp.org/newsletters/acutecare/articles/20100923.asp. Accessed January 15, 2012.
8. LewinJJJocobiJ.Society Critical Care Medicine. Drug shortages and quality care in the ICU. http://www.sccm.org/Publications/Critical-Connections/ Archives/April-2011/Pages/DrugShortages.aspx. Accessed December 10, 2011.
9. Wunsch H, Kahn JM, Kramer AA, et al. Use of intravenous infusion sedation among mechanically ventilated patients in the United States. Crit Care Med. 2009 ; 37 (12). 3031-3039
10. Jensen V, Rappaport BA. The reality of drug shortages - the case of the injectable agent propofol. N Engl J Med. 2010 ; 363 (9). 806-807
11. Carson SS, Kress JP, Rodgers JO, et al. A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients. Crit Care Med. 2006 ; 34 (5). 1326-1332
12. Cox CE, Reed SD, Govert JA, et al. Economic evaluation of propofol and lorazepam for critically ill patients undergoing mechanical ventilation. Crit Care Med. 2008 ; 36 (3). 706-714
13. Carasco G, Molina R, Costa J, et al. Propofol versus midazolam in short, medium, and long-term sedation of critically ill patients. Chest. 1993 ; 103 (2). 557-564
14. Hall RI, Sandham D, Cardinal P, et al. Propofol vs midazolam for ICU sedation: a Canadian multicenter randomized trial. Chest. 2001 ; 119 (4). 1151-1159
15. Barrientes-Vega R, Sanchez-Soria MM, Morales-Garcia C, et al. Prolonged sedation in critically ill patients with midazolam or propofol: impact on weaning and costs. Crit Care Med. 1997 ; 25 (1). 33-40
16. Jakob SM, Ruokonen E, Grounds RM, et al. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation two randomized controlled trials. JAMA. 2012 ; 307 (11). 1151-1160
17. Roberts R, Ruthazer R, Chi A, et al. Impact of a national propofol shortage on duration of mechanical ventilation at an academic medical center. Crit Care Med. 2012 ; 40 (2). 406-411
18. Reichert MG, Jones WA, Royster RL, et al. Effect of a dexmedetomidine substitution during a nationwide propofol shortage in patients undergoing coronary artery bypass graft surgery. Pharmacotherapy. 2011 ; 31 (7). 673-677
19. Wunsch H. Weighing the costs and benefits of a sedative. JAMA. 2012 ; 307 (11). 1195-1197
20. Devlin JW, Mallow-Corbett S, Riker RR. Adverse drug events associated with the use of analgesics, sedatives, and antipsychotics in the intensive care unit. Crit Care Med. 2010 ; 38 (suppl 6). S231 - S243
21. Pandharipande P, Shintani A, Peterson J, et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology. 2006 ; 104 (1). 21-26
22. Sessler CN, Varney K. Patient-focused sedation and analgesia in the ICU. Chest. 2008 ; 133 (2). 552-565
23. Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002 ; 30 (1). 119-141
24. Kress JP, Pohlman AS, O'Connor MF, et al. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med. 2000 ; 342 (20). 1471-1477
25. National Cancer Institute website. Cancer Statistics. http://www.cancer.gov/statistics. Accessed January 13, 2012.
26. IMS Institute for Healthcare Informatics. Drug Shortages: a closer look at products, suppliers and volume volatility. November 2011. http://www.imshealth.com/deployedfiles/ims/Global/Content/Insights/ IMS%20Institute%20for%20Healthcare%20Informatics/Static%20Files/ IHII-Drug-Shortage-Report.pdf. Accessed February 2, 2012.
27. Gatesman ML, Smith TJ. The shortage of essential chemotherapy drugs in the United States. N Engl J Med. 2011 ; 365 (18). 1653-1655
28. Food and Drug Administration. A review of FDA's approach to medical product shortages. U.S. Food and Drug Administration Web Site. www.fda.gov/DrugShortageReport. Accessed January 31, 2012.
29. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines. NCCN website. http://www.nccn.org/professionals/physician-gls/f- guidelines.asp. Accessed April 16, 2012.
30. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Colon Cancer. Version 3.2012. http://www.nccn.org/professionals/ physician-gls/pdf/colon.pdf. Accessed January 13, 2012.
31. Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008 ; 26 (12). 2006-2012
32. Rothenberg ML, Cox JV, Butts C, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol. 2008 ; 19 (10). 1720-1726
33. Ducreux M, Bennouna J, Hebbar M, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer. 2011 ; 128 (3). 682-690
34. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Hodgkin lymphoma (HL). Version 1.2012. NCCN Web Site. http://www.nccn.org/professionals/physician-gls/pdf/hodgkins.pdf. Accessed January 10, 2012.
35. Santoro A, Bonadonna G, Valagussa P, et al. Long-term results of combined chemotherapy-radiotherapy approach in hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol. 1987 ; 5 (1). 27-37
36. Biagi JJ, Raphael MJ, Mackillop WJ, et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA. 2011 ; 305 (22). 2335-2342
37. Kothari A, Fentiman IS. Diagnostic delays in breast cancer and impact on survival. Int J Clin Pract. 2003 ; 57 (3). 200-203
38. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Acute myeloid leukemia (AML). Version 2.2011. NCCN Web Site. http://www.nccn.org/professionals/physician-gls/pdf/aml.pdf. Accessed January 17, 2012.
39. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: randomized trial. Lancet. 2000 ; 355 (9215). 1588-1596
40. Jager E, Heike M, Bernhard H, et al. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. J Clin Oncol. 1996 ; 14 (8). 2274-2279
41. O'Connell MJ. A phase III trial of 5-fluorouracil and leucovorin in the treatment in the treatment of advanced colorectal cancer. Cancer. 1989 ; 63 (suppl 6). 1026-1030
42. Coalition of Cancer Cooperative Groups Web Site. http://www. cancertrialshelp.org. Accessed January 29, 2012.
43. Reducing prescription drug shortages. Presidential documents: Executive order 13588 of October 31, 2011. Federal Register;76:68295- 68296. Federal Register Web Site. http://www.gpo.gov/fdsys/pkg/FR-2011-11-03/pdf/2011-28728. pdf. Accessed February 2, 2012.
44. Applications for food and drug administration approval to market a new drug; revision of postmarketing reporting requirements - discontinuance. December 19, 2011. Federal Register;76: 78530-78540. Federal Register Web Site. https://www.federalregister.gov/articles/2011/12/19/2011-32354/ applications-for-food-and-drug-administration-approval-to-market-a-new-drug- revision-of. Accessed January 31, 2012.
45. A proposed law (S.296,2011) Preserving access to life-saving medications act 2011. The U.S. Government Printing Office Web Site. http://www.gpo.gov/ fdsys/pkg/BILLS-112s296is/pdf/BILLS-112s296is.pdf. Accessed February 2, 2012.
46. A proposed law (H.R.2245,2011) Preserving access to life-saving medications act 2011. The U.S. Government Printing Office Web Site. http://www.gpo.gov/fdsys/pkg/BILLS-112hr2245ih/pdf/BILLS-112hr2245ih.pdf. Access February 2, 2012.